Mineralys Therapeutics (MLYS) Earnings Date & Reports

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

MLYS is expected to report earnings to rise 10.20% to -108 cents per share on May 19

Mineralys Therapeutics MLYS Stock Earnings Reports

Q1'25

Est.

$-1.08

Q4'24

Missed

by $0.27

Q3'24

Missed

by $0.42

Q2'24

Missed

by $0.11

Q1'24

Beat

by $0.02

The last earnings report on February 12 showed earnings per share of -98 cents, missing the estimate of -70 cents. With 1.11M shares outstanding, the current market capitalization sits at 850.29M.

View a ticker or compare two or three

Compare

MLYS